{"id":4295,"date":"2025-08-07T10:35:28","date_gmt":"2025-08-07T07:35:28","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4295"},"modified":"2025-08-07T10:36:39","modified_gmt":"2025-08-07T07:36:39","slug":"keros-therapeutics-focuses-on-advancing-ker-065-for-duchenne-muscular-dystrophy-dmd","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/keros-therapeutics-focuses-on-advancing-ker-065-for-duchenne-muscular-dystrophy-dmd\/","title":{"rendered":"Keros Therapeutics, Duchenne Musk\u00fcler Distrofi (DMD) i\u00e7in KER-065&#039;yi Geli\u015ftirmeye Odaklan\u0131yor"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Keros Therapeutics, Duchenne kas distrofisi (DMD) i\u00e7in temel klinik program\u0131 olan KER-065&#039;nin geli\u015ftirilmesine y\u00f6nelik kaynaklar\u0131 yeniden tahsis etmek \u00fczere tasarlanm\u0131\u015f stratejik bir yeniden yap\u0131lanma duyurdu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Keros, \u015eirketin modern vizyonunu ve operasyonel oda\u011f\u0131n\u0131 desteklemek amac\u0131yla \u00e7e\u015fitli Y\u00f6netim Kurulu ve liderlik de\u011fi\u015fiklikleri duyurdu. Bu eylemler, Keros&#039;nin KER-065&#039;nin tedavi potansiyeline olan g\u00fcvenini yans\u0131t\u0131yor ve \u015eirket&#039;in hastalara anlaml\u0131 ve potansiyel olarak hastal\u0131\u011f\u0131 iyile\u015ftiren faydalar sa\u011flama misyonunu daha iyi yerine getirmesini sa\u011flayacak.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Keros Therapeutics \u0130cra Kurulu Ba\u015fkan\u0131 Dr. Jasbir S. Seehra, &quot;Keros&#039;nin hissedarlar ve hastalar i\u00e7in de\u011fer yaratma taahh\u00fcd\u00fc do\u011frultusunda, operasyonlar\u0131m\u0131z\u0131 basitle\u015ftirme ve Duchenne kas distrofisi (&quot;DMD&quot;) ile ya\u015fayan bireyler i\u00e7in terap\u00f6tik potansiyele sahip oldu\u011funa inand\u0131\u011f\u0131m\u0131z bir varl\u0131k olan KER-065&#039;yi geli\u015ftirmeye odaklanma karar\u0131 ald\u0131k,&quot; dedi. &quot;En umut verici klinik program\u0131m\u0131za \u00f6ncelik vererek, Keros&#039;nin hissedarlar i\u00e7in ek de\u011fer yaratmak \u00fczere daha y\u00fcksek hassasiyet ve aciliyetle \u00e7al\u0131\u015fmas\u0131n\u0131 bekliyoruz. Geli\u015fmi\u015f bir strateji, ak\u0131c\u0131 bir liderlik ve g\u00fc\u00e7l\u00fc bir klinik temelle, KER-065 i\u00e7in klinik geli\u015ftirmenin bir sonraki a\u015famas\u0131n\u0131 ba\u015flatmak i\u00e7in iyi bir konumda oldu\u011fumuza inan\u0131yoruz.&quot;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Daha fazla bilgi edin<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/tr\/keros-therapeutics-announces-initial-topline-results-from-the-phase-1-clinical-trial-of-ker-065-in-healthy-volunteers\/\">Keros Therapeutics, Sa\u011fl\u0131kl\u0131 G\u00f6n\u00fcll\u00fclerde KER-065&#039;nin 1. Faz Klinik Denemesinden \u0130lk \u00d6nemli Sonu\u00e7lar\u0131 Duyurdu<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u015eirket, daha \u00f6nce sa\u011fl\u0131kl\u0131 g\u00f6n\u00fcll\u00fcler \u00fczerinde y\u00fcr\u00fct\u00fclen KER-065 Faz 1 klinik \u00e7al\u0131\u015fmas\u0131n\u0131n ilk \u00f6nemli sonu\u00e7lar\u0131n\u0131 duyurmu\u015f ve \u00e7al\u0131\u015fma, g\u00fcvenlik, tolere edilebilirlik, farmakokinetik ve farmakodinamik a\u00e7\u0131lardan temel hedeflere ula\u015fm\u0131\u015ft\u0131r. \u015eirket, elde edilen g\u00fc\u00e7l\u00fc verilerin, program\u0131n DMD&#039;li hastalarda KER-065 Faz 2 klinik \u00e7al\u0131\u015fmas\u0131na ilerlemesini destekledi\u011fine inanmaktad\u0131r. \u015eirket, olumlu d\u00fczenleyici etkile\u015fimlere tabi olmak kayd\u0131yla, bu \u00e7al\u0131\u015fmay\u0131 2026 y\u0131l\u0131n\u0131n ilk \u00e7eyre\u011finde ba\u015flatmay\u0131 planlamaktad\u0131r.<\/p>","protected":false},"excerpt":{"rendered":"<p>Keros Therapeutics announced a strategic realignment designed to reallocate resources towards the development of its key clinical program, KER-065 for Duchenne muscular dystrophy (DMD). Keros announced several Board of Directors and leadership transitions intended to support the Company\u2019s streamlined vision and operational focus. These actions reflect Keros\u2019 confidence in the therapeutic potential of KER-065 and [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4297,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[337,336],"class_list":["post-4295","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-ker-065","tag-keros-therapeutics"],"subtitle":"Keros Therapeutics, operasyonlar\u0131 basitle\u015ftirme ve yaln\u0131zca Duchenne kas distrofisi (DMD) i\u00e7in KER-065'yi geli\u015ftirmeye odaklanma karar\u0131 ald\u0131.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/4295","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=4295"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/4295\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/4297"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=4295"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=4295"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=4295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}